Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 Maintenance in Resected High-Risk Pancreatic Cancer
NCT06779318Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tegafur in pancreatic cancer (PC) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Disease-Free Survival at 3 years. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06779318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06779318.